Team of Mercy's 12th 'Surviving the Color' set for May 17
'Everybody is invited,' Christina Crist, Executive Director for Team of Mercy, said. 'Get your dogs, get your grandparents, get your parents, get your kids, get your youth group, your athletic teams, get whoever, your friends. Grab someone that you know is struggling, most importantly.'
The event is organized by the Team of Mercy to raise awareness for suicide prevention while honoring lives lost.
The day begins at 9:00 a.m. at Brown and Ohio Streets in Terre Haute with an opening ceremony. The ceremony includes guest speakers and a butterfly release.
WATCH: Paint the Town Pink to raise funds for mammograms
'Life is taken away when someone takes their life,' Crist said. 'So, we incorporated the butterfly release to show giving life back into our community.'
The 5K run winds through Deming Park, where participants will be covered in color. After the run, food, music, and mental health resources will be available.
'I didn't know or understand how much mental health and suicide affected our area until it happened to me,' Crist said. 'So, I want to reach those individuals who are in my shoes.'
Crist lost her 15-year-old daughter Hannah to suicide.
'My why is all of the Hannahs out there, who struggle a silent battle of stigma, or whatever it may be, that is silent, and they think that they're alone,' Christ said.
Registration is underway now. In order to receive a t-shirt, registration must be completed by Friday, May 9. Participants can sign up until the day of the race, but will not receive a t-shirt after that date. To sign up for the race, click here. For more information on Team of Mercy, click here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
42 minutes ago
- Business Wire
Spok Sets Date to Report Second Quarter 2025 Results
PLANO, Texas--(BUSINESS WIRE)--Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced it will release its second quarter 2025 operating results on Wednesday, July 30, 2025, after the close of the U.S. financial markets. Management will host a conference call and webcast to discuss these financial results on Wednesday, July 30, 2025, at 5:00 p.m. ET. The presentation is open to all interested parties and may include forward-looking information. Conference Call Details To access the call, please dial in approximately ten minutes before the start of the call. For those unable to join the live call, an OnDemand version of the webcast will be available following the call under the URL link and on the investor relations website. About Spok Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Plano, Texas, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Care Connect® platform to enhance workflows for clinicians and support administrative compliance. Our customers send over 70 million messages each month through their Spok® solutions. Spok enables smarter, faster clinical communication. Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.
Yahoo
6 hours ago
- Yahoo
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
SAN DIEGO and CALGARY, AB, July 23, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, hosted a key opinion leader (KOL) webinar featuring leading physicians in the fields of oncology and immunotherapy discussing pelareorep's robust clinical data and how it fits in the evolving treatment landscape for pancreatic and gastrointestinal (GI) cancers. The KOLs provided individual presentations and then participated in a roundtable Q&A discussion. A replay of the full conversation can be found by clicking here. A selection of key takeaways includes: The meaningful survival benefit demonstrated by pelareorep-based treatment combinations in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC) patients across randomized and single-arm clinical studies necessitates evaluating pelareorep in a registration-enabling study in 1L mPDAC. Immunotherapies have not yet been approved to treat mPDAC patients, illustrating an unmet need, which provides an opportunity for an immunologically active agent like pelareorep to deliver an impactful clinical benefit in this challenging indication. The combination of pelareorep and chemotherapy would be an appealing treatment option for 1L mPDAC patients, even with the presence of RAS inhibitors in the treatment paradigm. Translational data from multiple mPDAC and colorectal cancer clinical trials validate pelareorep's mechanism of action, showing that it replicates in tumors, stimulates chemokine expression, and induces the expansion of tumor-infiltrating lymphocytes (TILs), which correlates with a reduction in tumor size. "I want to thank our esteemed panel of oncologists for their meaningful contributions to our KOL event," said Jared Kelly, Chief Executive Officer of Oncolytics. "Their insights underscore a critical and timely message: pelareorep is a compelling immunotherapy platform that is well situated for combination strategies and a highly differentiated asset for pharma partners looking to expand or establish leadership in GI oncology. We are committed to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers." About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For more about Oncolytics, please visit: or follow the company on social media on LinkedIn and on X @oncolytics. This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our commitment to moving forward aggressively toward registrational development while engaging with partners who share our vision of transforming outcomes in these difficult-to-treat cancers; our plans to advance pelareorep into registration enabling studies in metastatic breast cancer and pancreatic cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws. Company Contact Jon PattonDirector of IR & Communicationjpatton@ Investor Relations for Oncolytics Mike MoyerLifeSci Advisors+1-617-308-4306mmoyer@ Media Contact for Oncolytics Owen BlaschakLifeSci Communicationsoblaschak@ Logo - View original content to download multimedia: SOURCE Oncolytics Biotech® Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Adia Nutrition Inc. Supports Heroes and Their Families with TRICARE In-Network Application, Advancing Regenerative Care Through Adia Med
Winter Park, Florida--(Newsfile Corp. - July 23, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded leader in regenerative medicine and personalized wellness solutions, is thrilled to announce that its medical subsidiary, Adia Med, has officially filed to become an in-network provider with TRICARE, the healthcare program serving approximately 9.5 million active-duty service members, retirees, National Guard and Reserve members, and their families worldwide. This step, paired with Adia Med's anticipated approval as a United Healthcare provider by August 1, 2025, positions the company to transform healthcare access for millions. Adia Med expects to secure TRICARE in-network provider status by August 31, 2025, tapping into a program that paid out $50.6 billion for medical treatments in FY2019 to support its beneficiaries. Evaluation of the TRICARE Program: Fiscal Year 2019 Report to Congress. To view an enhanced version of this graphic, please visit: This strategic filing positions Adia Med to serve TRICARE's extensive network of beneficiaries, including military personnel and their families, by offering innovative regenerative treatments such as Umbilical Cord Blood Stem Cell (UCB-SC) therapies, Autologous Hematopoietic Stem Cell Transplantation (AHSCT), and Therapeutic Plasma Exchange (TPE). These therapies, provided at Adia Med's Winter Park clinic and planned satellite locations, target conditions like Multiple Sclerosis, joint pain, torn tendons, and other orthopedic and wellness needs, aligning with Adia Nutrition's mission to revolutionize healthcare accessibility. "We're fired up to support the 9.5 million TRICARE beneficiaries, including our nation's military heroes and their families, by bringing our regenerative therapies into their reach," said Larry Powalisz, CEO of Adia Nutrition Inc. "With TRICARE's massive $50.6 billion investment in medical care, our filing to join their network, alongside our imminent United Healthcare approval, will make advanced treatments more accessible and affordable, driving transformative health outcomes and fueling Adia Med's growth." The TRICARE filing complements Adia Med's recent progress with United Healthcare, where the company has already begun submitting its first patient insurance claims, signaling near-final integration. By securing in-network status with both TRICARE and United Healthcare, Adia Med will join an elite group of providers meeting rigorous standards for clinical excellence, compliance, and patient care. These partnerships will enable insurance reimbursement for Adia Med, enhancing affordability and accessibility for patients seeking innovative treatments. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio
